The EPO published patent application EP3681879A1 for octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2, a protein tyrosine phosphatase implicated in cancer cell signaling pathways. The patent identifies Krouzon Pharmaceuticals, Inc. as applicant with inventors Volkmann, Marfat, Nelson, and Zagouras. The granted claims cover compounds useful for treating cancers, classified under IPC codes C07D 403/04, C07D 401/14, A61P 35/00, A61K 31/497, and A61K 31/506.

Patent holders and licensees should verify freedom-to-operate for SHP2 inhibitor development programs and ensure proper patent term monitoring. Generic pharmaceutical manufacturers should assess patent coverage before entering markets for competing SHP2-targeted oncology therapies. The patent is enforceable across 36 European contracting states including Germany, France, the UK, Italy, Spain, and other EPC members.